Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Key Takeaways Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The ...

April 30 (Reuters) - (To receive the full newsletter in your inbox for free sign up here) An experimental Boehringer Ingelheim drug achieved “unprecedented” benefits in patients with an ...

Your Keytruda treatment may last for around 2 years, but certain factors may mean that you’ll receive the drug for a longer or shorter time. If you have questions about what to expect from your ...

Keytruda belongs to a class of medications called programmed death receptor-1 blocking antibodies (PD1-blocking antibodies). These drugs work by binding to certain parts of cells. This action ...

Merck sees a significant market opportunity for subcutaneous Keytruda. The company has projected that the biggest demand for a subcutaneous formulation will come from patients with early-stage ...

Merck & Co.’s cancer immunotherapy Keytruda is one of the pharmaceutical industry’s biggest successes. The drug's arrival in 2014 introduced a new way of treating cancer and, over time, it became ...

In this update, which will be similar in structure to my 2021 article, I will discuss the exposure of the six major constituents of PJP (see below) to the U.S. market in terms of addressable sales ...